Drugs /

epcoritamab

Back to Drugs List

Overview

NCI Definition [1]:
A bispecific monoclonal antibody, with potential immunomodulating and antineoplastic activities. Epcoritamab contains two antigen-recognition sites: one for human CD3, a T-cell surface antigen, and one for human CD20, a tumor-associated antigen (TAA) that is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. Upon administration, epcoritamab binds to both T-cells and CD20-expressing B-lineage tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against the CD20-expressing tumor B-cells.

Clinical Trials

View Clinical Trials for epcoritamab

Epcoritamab has been investigated in 5 clinical trials, of which 5 are open and 0 are closed. Of the trials investigating epcoritamab, 4 are phase 1/phase 2 (4 open) and 1 is phase 3 (1 open).

MS4A1 Expression, BCL2 Fusion, and BCL6 Fusion are the most frequent biomarker inclusion criteria for epcoritamab clinical trials.

Diffuse large B-cell lymphoma, follicular lymphoma, and high grade B-cell lymphoma, not otherwise specified are the most common diseases being investigated in epcoritamab clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Epcoritamab
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating epcoritamab and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
gen3013, gen-3013, gen 3013, duobody-cd3xcd20, anti-cd33/cd3 antibody gem 333, anti-cd20/cd3 bispecific antibody gen3013
Drug Target(s) [2]:
CD3D, CD3E, CD3G, MS4A1
NCIT ID [1]:
C163022

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.